Vicore Pharma Holding (NASDAQ:VCRE – Get Free Report) was the recipient of a large drop in short interest during the month of October. As of October 15th, there was short interest totaling 1,028 shares, a drop of 75.7% from the September 30th total of 4,238 shares. Based on an average daily volume of 27,277 shares, the short-interest ratio is currently 0.0 days.
Wall Street Analyst Weigh In
A number of research firms recently issued reports on VCRE. Wall Street Zen upgraded Vicore Pharma to a “hold” rating in a research note on Saturday, October 24th. Weiss Ratings assumed coverage on shares of Vicore Pharma in a research report on Thursday, October 8th. They issued a “sell (e-)” rating on the stock. Finally, Jefferies Financial Group assumed coverage on shares of Vicore Pharma in a research note on Friday, October 9th. They issued a “buy” rating and a $25.00 target price for the company. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Vicore Pharma presently has a consensus rating of “Hold” and an average target price of $25.00.
Get Our Latest Research Report on VCRE
Vicore Pharma Trading Down 2.0%
NASDAQ VCRE opened at $10.00 on Friday. Vicore Pharma has a one year low of $7.88 and a one year high of $17.80.
Vicore Pharma (NASDAQ:VCRE – Get Free Report) last released its earnings results on Friday, August 21st. The company reported ($0.05) EPS for the quarter. The business had revenue of $0.23 million for the quarter.
About Vicore Pharma
Vicore Pharma is a Swedish clinical-stage biopharmaceutical company focused on developing treatments for severe respiratory diseases, particularly pulmonary fibrosis and other conditions involving lung injury and impaired tissue repair. The company is headquartered in Gothenburg, Sweden, and conducts research and clinical development activities aimed at addressing significant unmet medical needs.
Vicore’s lead drug candidate is buloxibutid, also known as C21, an oral small-molecule agonist of the angiotensin II type 2 receptor.
Read More
- Five stocks we like better than Vicore Pharma
- Chipotle’s $32 Floor: Is a Major Stock Rebound Coming?
- SaaS-Pocalypse II: Is ServiceNow’s Sell-Off Another Buying Opportunity?
- Robinhood Stock Is Down Nearly 37%—So Why Is Wall Street Still So Bullish?
- 5 Stocks to Buy in November: Bargains Worth Giving Thanks For
Receive News & Ratings for Vicore Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vicore Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
